Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2016 | Research

EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma

Authors: Xiao Chen, Xuan Wang, Xue Wei, Jiandong Wang

Published in: Journal of Ovarian Research | Issue 1/2016

Abstract

Background

Ovarian serous carcinoma (OSC) is the most common ovarian epithelial malignancy. Disregulation of Eph/ephrin signaling has been implicated in oncogenesis and tumor progression. EphA5 receptor is one of large families of Eph tyrosine kinase receptor and is documented in the development of nervous system. Till now, there is no published data about the role of EphA5 in ovarian epithelial neoplasmas.

Methods

This study aims to investigate the expression of EphA5 protein in ovarian serous carcinoma, and its relationship to clinical pathological characteristics. Sixty-one cases of ovarian serous carcinoma, 24 cases of benign ovarian serous tumors, 42 cases of serous borderline tumors and 20 cases of normal fallopian tubes were examined using immunohistochemical staining. The relationship between EphA5 expression and pathological parameters was analyzed. Kaplan-Meier survival function was used to analyze prognosis of patients.

Results

Immunostaining analysis demonstrated that the EphA5 protein was highly expressed in 100% (20/20) of normal fallopian tube samples, 100% (24/24) of benign epithelial ovarian tumors, 76% (32/42) of ovarian serous borderline tumors, and 31% (19/61) of ovarian serous carcinomas. Loss of EphA5expression was associated with tumor grade (P < 0.001) and FIGO stage (P = 0.005). The survival analysis showed that patients with negative or weak expression of EphA5 protein had a poor outcome than those with positive expression (P = 0.004).

Conclusions

Our results show that EphA5 may be a potential biomarker for distinguishing high-and low-grade ovarian serous carcinoma and a potential prognostic marker.

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, et al. A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014;20(3):711–23.CrossRefPubMed

Sherman-Baust CA, Kuhn E, Valle BL, Shih Ie M, Kurman RJ, Wang TL, et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol. 2014;233(3):228–37.CrossRefPubMedPubMedCentral

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol. 2004;35(6):663–9.CrossRefPubMed

Bhagat R, Premalata CS, Shilpa V, Pallavi VR, Ramesh G, Vijay CR, et al. Altered expression of beta-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma. Tumour Biol. 2013;34(4):2459–68.CrossRefPubMed

Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267–82.CrossRefPubMedPubMedCentral

O’Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29(8):1034–41.PubMed

Numachi Y, Yoshida S, Yamashita M, Fujiyama K, Toda S, Matsuoka H, et al. Altered EphA5 mRNA expression in rat brain with a single methamphetamine treatment. Neurosci Lett. 2007;424(2):116–21.CrossRefPubMed

Wu YJ, Xu MY, Wang L, Sun BL, Gu GX. Analysis of EphA5 receptor in the developing rat brain: an in vivo study in congenital hypothyroidism model. Eur J Pediatr. 2013;172(8):1077–83.CrossRefPubMed

Mamiya PC, Hennesy Z, Zhou R, Wagner GC. Changes in attack behavior and activity in EphA5 knockout mice. Brain Res. 2008;1205:91–9.CrossRefPubMedPubMedCentral

10.

Yamada T, Yuasa M, Masaoka T, Taniyama T, Maehara H, Torigoe I, et al. After repeated division, bone marrow stromal cells express inhibitory factors with osteogenic capabilities, and EphA5 is a primary candidate. Bone. 2013;57(2):343–54.CrossRefPubMed

11.

Petkova TD, Seigel GM, Otteson DC. A role for DNA methylation in regulation of EphA5 receptor expression in the mouse retina. Vision Res. 2011;51(2):260–8.CrossRefPubMed

12.

Caras IW. A link between axon guidance and axon fasciculation suggested by studies of the tyrosine kinase receptor EphA5/REK7 and its ligand ephrin-A5/AL-1. Cell Tissue Res. 1997;290(2):261–4.CrossRefPubMed

13.

St John JA, Tisay KT, Caras IW, Key B. Expression of EphA5 during development of the olfactory nerve pathway in rat. J Comp Neurol. 2000;416(4):540–50.CrossRefPubMed

14.

Fu DY, Wang ZM, Wang BL, Chen L, Yang WT, Shen ZZ, et al. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol. 2010;41(1):48–58.CrossRefPubMed

15.

Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, Kouraklis G, Chatzopoulou E, Dimakopoulou K, et al. Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res. 2010;16(2):267–76.CrossRefPubMed

16.

Gu Y, Li F, Qian N, Chen X, Wang H, Wang J. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival. J Clin Pathol. 2016;69(5):448-53.

17.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, et al. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev. 2015;41(2):136–43.CrossRefPubMed

18.

Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012;118(12):3087–94.CrossRefPubMed

19.

Singh N, Ayhan A, Menon U, Chin Aleong JA, Faruqi AZ, Gayther SA, et al. Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems. Histopathology. 2008;52(3):393–5.CrossRefPubMed

20.

Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, et al. Downregulation of EphA5 by promoter methylation in human prostate cancer. BMC Cancer. 2015;15:18.CrossRefPubMedPubMedCentral

21.

Kober P, Bujko M, Oledzki J, Tysarowski A, Siedlecki JA. Methyl-CpG binding column-based identification of nine genes hypermethylated in colorectal cancer. Mol Carcinog. 2011;50(11):846–56.CrossRefPubMed

Title: EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma
Authors: Xiao Chen
Xuan Wang
Xue Wei
Jiandong Wang
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2016
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-016-0292-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Molecular manipulation of keratin 8/18 intermediate filaments: modulators of FAS-mediated death signaling in human ovarian granulosa tumor cells

Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease

Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

Sertoli - Leydig cell tumor with retiform areas and overgrowth of rhabdomyosarcomatous elements: case report and literature review

Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein

MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer